Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

COVID-19 booster programme

AstraZeneca AZ

AstraZeneca’s Brilinta reduces rate of secondary stroke

Drug helps to prevent rate of stroke and death by 17%

- PMLiVE

Novartis reveals plans for a zero-profit COVID-19 drugs portfolio

Includes 15 medicines from company's generics division

- PMLiVE

Healthineers’ COVID-19 antibody test proves most effective in comparative study

Beats tests from Roche, Abbott and DiaSorin

- PMLiVE

Moderna’s COVID-19 vaccine produces immune response in early trial

Antibodies observed in all participants tested

- PMLiVE

Medicago doses first patients with plant-derived COVID-19 vaccine

Study will evaluate candidate alone or in combination with an adjuvant

- PMLiVE

FDA fast-tracks Pfizer/BioNTech’s COVID-19 vaccine candidates

Two investigational candidates granted accelerated review

- PMLiVE

Gilead reports remdesivir cuts risk of death in severe COVID-19 patients

Also reveals new analyses from compassionate use programme

- PMLiVE

France’s Osivax raises over €30m for universal flu and coronavirus vaccines

Company’s technology designed to train immune system to recognise internal virus proteins

- PMLiVE

Novavax gets $1.6bn from US government for coronavirus vaccine

Latest company to join Operation Warp Speed

- PMLiVE

Moderna clashes with US scientists over pivotal COVID-19 vaccine trials

Delays allegedly resulting from a lack of cooperation

- PMLiVE

GSK signs deal with Medicago for COVID-19 vaccine

Collaboration will utilise GSK’s pandemic adjuvant platform

AstraZeneca AZ

EU gives AZ’s Lynparza green light for BRCA-mutated pancreatic cancer

PARP inhibitor now available for rare, life-threatening disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links